Benefits advisors need to stay proactive and help their clients leverage formulary design, clinical oversight, and ...

Doug Long, BA, MBA, vice president of Industry Relations at IQVIA, shares what's happening in the growing GLP-1 and biosimilars space. Long was a presenter at the annual AMCP 2025 meeting in Houston, ...

Learn more about whether Alvotech or Legend Biotech Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The APPA, if passed into law, puts an upper limit of 20 patents, but only of certain types of patents (see below), that can be asserted in a BPCIA litigation (the APPA does not affect ANDA litigations ...

Co-production deals with adalimumab biosimilar manufacturers and PBMs have increased biosimilar adoption, but this ...

AbbVie’s stock is having a glow-up, climbing 16.1% in 2025, leaving the industry and S&P 500 behind in the dust. The company deftly pivoted after Humira’s fall from patent grace by betting big on ...

Rising biosimilar adoption, shifting market dynamics, and escalating supply chain vulnerabilities are driving change in ...

MSD’s monoclonal antibody, indicated for 15 types of cancer, smashed industry records with sales of $27.3 billion in 2024, ...

Boehringer Ingelheim picked a challenging day to reveal its 2024 financial results and guidance for this year. | Boehringer ...

Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return ...

CVS Caremark, Express Scripts and Optum Rx — the three largest pharmacy benefit managers in the U.S. — each excluded more ...

As the biosimilar industry celebrates a decade of growth, the market continues to evolve with expanded treatment options, ...